Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ResMedRSMDF 94 Return-on-Tangible-Asset is 30.84% as of Mar. 2026, which is 19% above its 10-year median of 25.91. GuruFocus rates RSMDF with a GF Score™ of 94/100 and a GF Value™ of $23.07 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 857 Medical Devices & Instruments companies, ResMed ranks better than 98.25% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. ResMed's annualizedNet Income for the quarter that ended in Mar. 2026 was $1,595 Mil. ResMed's average total tangible assets for the quarter that ended in Mar. 2026 was $5,172 Mil. Therefore, ResMed's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 30.84%.
The historical rank and industry rank for ResMed's Return-on-Tangible-Asset or its related term are showing as below:
RSMDF'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 16.09 Med: 25.91 Max: 34.13
Current: 31.51
During the past 13 years, ResMed's highest Return-on-Tangible-Asset was 34.13%. The lowest was 16.09%. And the median was 25.91%.
RSMDF's Return-on-Tangible-Asset is ranked better than 98.25% of 857
companies
in the Medical Devices & Instruments industry
Industry Median: 0.57
vs RSMDF: 31.51
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
ResMed Return-on-Tangible-Asset Related Terms
ResMed Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for ResMed's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RSMDF vs MDLN, WST, BDX: Return-on-Tangible-Asset Comparison
For the Medical Instruments & Supplies subindustry, ResMed's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ResMed Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ResMed's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where ResMed's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 30.84% mean?
ResMed (RSMDF) has a Return-on-Tangible-Asset of 30.84% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on ResMed and its competitors. This is 19% above median its historical median of 25.91. Over the past decade, ResMed's Return-on-Tangible-Asset has ranged from 16.09 to 34.13. According to the industry distribution chart, ResMed ranks #15 out of 857 companies in the Medical Devices & Instruments industry, placing it in the top 1.8%.
Is ResMed's Return-on-Tangible-Asset too high?
ResMed's current Return-on-Tangible-Asset of 30.84% is 19% above median its 10-year median of 25.91. Over the past 10 years, this metric has ranged from a low of 16.09 to a high of 34.13. The Medical Devices & Instruments industry median Return-on-Tangible-Asset is 0.57. ResMed's value of 30.84% is 5310.5% above this industry median. Based on the distribution chart, ResMed ranks #15 out of 857 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, ResMed has a GF Score™ of 94/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ResMed's Return-on-Tangible-Asset compare to MDLN and WST?
According to the Medical Devices & Instruments industry distribution chart, ResMed ranks #15 out of 857 companies for Return-on-Tangible-Asset. This places ResMed in the top 2% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 0.57. ResMed's value of 30.84% is 5310.5% above this benchmark. Historically, ResMed's own Return-on-Tangible-Asset has ranged from 16.09 to 34.13 over the past decade. While the company's 10-year median is 25.91 vs. the industry median of 0.57, ResMed has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.57, based on 857 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ResMed's current Return-on-Tangible-Asset of 30.84% is 5310.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on ResMed and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ResMed's current Return-on-Tangible-Asset is 30.84%, which is 19% above median its own 10-year median of 25.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ResMed stock overvalued right now?
Based on GuruFocus' analysis, ResMed (RSMDF) is currently considered Modestly Undervalued. The stock's GF Value™ is $23.07, compared to a current price of $16.72 — trading 27.5% below its estimated fair value. The current Return-on-Tangible-Asset is 30.84%, which is 19% above median its 10-year median of 25.91 and 5310.5% above the Medical Devices & Instruments industry median of 0.57. ResMed's overall GF Score™ is 94/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For ResMed (RSMDF), the current Return-on-Tangible-Asset is 30.84% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ResMed (RSMDF) Overvalued in 2026?
Based on GuruFocus' analysis, ResMed stock appears to be undervalued.
The current stock price of $16.72 is trading 27.5% below its estimated GF Value™ of $23.07.
GuruFocus considers ResMed to be Modestly Undervalued.
Key valuation signals for RSMDF:
Return-on-Tangible-Asset: 30.84% (19% above median its 10-year median of 25.91)
GF Value™: $23.07 vs. price of $16.72 (27.5% below fair value)
Industry Position: 5310.5% above the Medical Devices & Instruments median (#15 of 857)
No single metric tells the full story. See the RSMDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
94GF Score
Get the complete analysis for RSMDF
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RSMDF has been successfully added to your 
